Share

MEDIPOST Co., Ltd. Stocks

26550Last Updated 28.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₩ 702.99M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
26550
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. It operates through the following business divisions: Cord Blood Bank, Stem Cell Therapy, Health Functional Food, Import and Distribution of Natural Cosmetics and Healthcare Services. The Cord Blood Bank division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapy division manufactures allogeneic stem cell drug products. The Health Functional Food division offers vitamins and nutritional supplements. The Import and Distribution of Natural Cosmetics division is involved in the sales and marketing of natural cosmetics imported by Pevonia Inc. The Healthcare Services division provides healthcare solutions such as bizcare, insu-care, affiliate, telehealth services and medical devices through web, mobile, and call centers. The company was founded by Yoon-Sun Yang and Won-Il Oh on June 26, 2000 and is headquartered in Seongnam, South Korea.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks